Predictors of Poor Response to Salvage Chemotherapy in Relapsed/ Refractory Pediatric Hodgkin Lymphoma- A Retrospective Analysis from Tertiary Cancer Centre in India

ABSTRACT

Background: Previous studies identified prognostic factors for survival in relapsed pediatric Hodgkin lymphoma (HL) who received salvage chemotherapy followed by autologous stem cell transplant (ASCT). However, data regarding predictors of poor response to salvage chemotherapy is limited.

Methods: We conducted retrospective study in all relapsed HL treated from January 2003 to December 2013. Logistic regression analysis was done to identify predictors of response to salvage chemotherapy. Cox regression analysis was done to identify prognostic factors for Freedom from treatment failure (FFTF) and overall survival (OS).

Results: Forty six patients had relapsed HL. Among 45 patients who received salvage chemotherapy only 34 (73.4%) underwent ASCT. Stage 4 disease (p=0.02) and bulky disease at relapse (p=0.03) were predictors of poor response to salvage chemotherapy. FFTF and OS at 5 yr for entire cohort were 50.1% and 63.3%, respectively, while the same for patients who underwent ASCT were 66.3% and 80.7%, respectively. Among ASCT patients, those who had primary refractory /early relapse [HR-4.7, (95% CI-1, 22); p=0.05] had significant impact on 5 yr FFTF whereas disease status at transplant (CR vs. No CR) had significant impact on 5 yr OS [HR-4.6, (95% CI-1.03, 20.5); p=0.04].

Conclusions: Identification of predictors of poor response to salvage chemotherapy is an unmet need in the management of pediatric HL since complete response (CR) before transplant is independent predictor of survival. Stage 4 and bulky disease at relapse are high risk factors to predict incomplete response. Future trials should explore newer agents for effective salvage for these patients to attain complete response before ASCT.

Keywords

relapsed hodgkin lymphoma - risk factor - poor response

Publication History

Article published online:
09 May 2020

• References

• 1 Satwani P, Ahn KW, Carreras J, et al (2015). A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 50(11): 1416-1423.
• 2 Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL (2006). APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer 46(3): 320-324.
• 3 Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG; United Kingdom Children's Cancer Study Group (2004). Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 26(11): 740-745.
• 4 Trippett TM, Schwartz CL, Guillerman RP, et al (2015). Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer 62(1): 60-64.
• 5 Gorde-Grosjean S, Oberlin O, Leblanc T, et al (2012). Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol 158(5): 649-656.
• 6 Schellong G, Dörffel W, Claviez A, et al (2005). Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 23(25): 6181-6189.
• 7 Williams CD, Goldstone AH, Pearce R, et al (1993). Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 11(11): 2243-2249.
• 8 Baker KS, Gordon BG, Gross TG, et al (1999). Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 17(3): 825-831.
• 9 Akhtar S, El Weshi A, Rahal M, Abdelsalam M, Al Husseini H, Maghfoor I (2010). High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 45(3): 476-482.
• 10 Lieskovsky YE, Donaldson SS, Torres MA, et al (2004). High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 22(22): 4532-4540.
• 11 Majhail NS, Weisdorf DJ, Defor TE, et al (2006). Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 12(10): 1065-1072.
• 12 Hazar V, Kesik V, Aksoylar S, et al (2015). Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma. Pediatr Transplant 19(7): 745-752.
• 13 Shafer JA, Heslop HE, Brenner MK, et al (2010). Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma 51(4): 664-670.
• 14 Metzger ML, Hudson MM, Krasin MJ, et al (2010). Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer 116(18): 4376-4384.
• 15 Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD (2014). Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood Cancer 61(4): 579-586.
• 16 Lister TA, Crowther D, Sutcliffe SB, et al (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7(11): 1630-1636.
• 17 Cheson BD, Pfistner B, Juweid ME, et al (2007). Revised response criteria for malignant lymphoma. J Clin Oncol 25(5): 579-586.
• 18 Hazar V, Kesik V, Aksoylar S, et al (2015). Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma. Pediatr Transplant 19(7): 745-752.